sales@scalarmarketresearch.com |  +1-800-213-5170  (U.S./ Canada Toll-free) |  REGISTER |  SIGN IN

Home >> Reports >> infantile spasms therapeutics market

report

Infantile Spasms Therapeutics Market, By Dosage (Liquid, Solid), by Roa (Oral, Parenteral) – Global Revenue, Trends, Growth, Share, Size and Forecast To 2022

HC275 March 2017 100+ FREE 10% CUSTOMIZATION

Infantile Spasms is a rare seizure condition occurs to young children. It usually occurs in children under one year of age, the average age is considered four months but in few children, it may happen as late as two years. It is very difficult for parents as well as pediatricians to realize the condition as it appears in a very subtle way. The goal of Infantile Spasms Therapeutics is to achieve complete control on the spasms. The medical treatment options are limited; so far only two drugs have been approved by FDA, Adrenocorticotropic hormone (ACTH) and Vigabatrin.

The report tracks the major market events including product launches, technological developments, mergers & acquisitions, and the innovative business strategies opted by key market players. Along with strategically analyzing the key micro markets, the report also focuses on industry-specific drivers, restraints, opportunities and challenges in the Infantile Spasms Therapeutics Market. The scope of this report covers the Infantile Spasms Therapeutics Market by its major segments, which include the types, applications, and the major geographic regions.

KEY BENEFITS OF THE REPORT

  • In-depth analysis of the market ecosystem and its impact on the revenue growth
  • Understanding of the strategies that are being adopted by the key players in this market to stay competitive
  • Valuable insights into the key technological and market trends impacting this market

KEY PREMIUM INDUSTRY INSIGHTS

  • The key reasons driving the growth of the Infantile Spasms Therapeutics market includes increasing the prevalence of Infantile Spasms, and new technological advancement in the medical imaging technology.
  • New drug development is one of the key growth opportunity drivers for this market.
  • However, factors like low success rate may hamper the growth of the Infantile Spasms Therapeutics Market.

RESEARCH METHODOLOGY

The research methodology for Scalar Market Research’s infantile spasms therapeutics market report utilizes a combination of top-down and bottom-up research formats. Our primary focus on continuous market tracking, rigorous fact-checking, data-triangulation, and multiple layers of quality control ensures high-quality data that can be leveraged for actionable research insights.

To know about the assumptions considered for the study, Download PDF Sample.

MARKET SEGMENTATION

This report analyzes the infantile spasms therapeutics market by the following segments:

  • Infantile Spasms Therapeutics Market, by Dosage
    • Liquid
    • Solid
  • Infantile Spasms Therapeutics Market, by Roa
    • Oral
    • Parenteral

KEY MARKET PLAYERS

Key players in the infantile spasms therapeutics market include:

  • Anavex Life Sciences Corp
  • H. Lundbeck A/S
  • INSYS Therapeutics, INC.
  • CatalystPharma
  • GW Pharmaceuticals, plc.
  • Retrophin, Inc.
  • Mallinckrodt
  • ORPHELIA Pharma SA
  • Valerion Therapeutics

GEOGRAPHIC COVERAGE AND ANALYSIS

This granular market research report covers the following geographic regions in great detail:

  • NORTH AMERICA
    • U.S.
    • Rest of North America
  • EUROPE
    • France
    • Germany
    • U.K.
    • Rest of Europe
  • ASIA-PACIFIC
    • China
    • India
    • Japan
    • Rest of Asia-Pacific
  • MIDDLE EAST & AFRICA
    • GCC
    • North Africa
    • South Africa
    • Rest of Middle East & Africa
  • LATIN AMERICA
    • Brazil
    • Rest of Latin America

TRENDING RELATED REPORT

Dental Equipment Market, by Product (Dental Laser, Dental Radiology Equipment, Systems & Parts, Other Equipment, Hygiene & Maintenance Devices, Laboratory Machines), End-Users (Hospitals & Clinics, Laboratories) - Global Revenue, Trends, Growth, Share, Size and Forecast to 2022


  1. MARKET OVERVIEW
    1. Market Definitions
    2. Research Methodology
    3. Market Segmentation
  2. EXECUTIVE SUMMARY
  3. MARKET DYNAMICS
    1. Drivers
    2. Restraints
    3. Opportunities
    4. Premium Industry Trends
  4. INDUSTRY ANALYSIS
    1. Value Chain Analysis
    2. Product Roadmap
  5. INFANTILE SPASMS THERAPEUTICS MARKET, BY DOSAGE
    1. Segment Share
    2. Dosage
      1. Liquid
      2. Solid
  6. INFANTILE SPASMS THERAPEUTICS MARKET, BY ROA
    1. Segment Share
    2. ROA
      1. Oral
      2. Parenteral
  7. INFANTILE SPASMS THERAPEUTICS MARKET, BY GEOGRAPHY
    1. North America
      1. By Country
        1. U.S.
        2. Rest of North America
      2. By Dosage
      3. By ROA
    2. Europe
      1. By Country
        1. France
        2. Germany
        3. U.K.
        4. Rest of Europe
      2. By Dosage
      3. By ROA
    3. Asia-Pacific
      1. By Country
        1. China
        2. India
        3. Japan
        4. Rest of Asia-Pacific
      2. By Dosage
      3. By ROA
    4. Rest of the World
      1. By Country
        1. Latin America
        2. Middle East & Africa
      2. By Dosage
      3. By ROA
  8. COMPETITIVE LANDSCAPE
    1. Market Share Analysis, 2015 (%)
    2. Key Innovators
  9. KEY MARKET PLAYERS
    1. Anavex Life Sciences Corp
      1. Overview
      2. Key Strategies
      3. Recent Developments
    2. H. Lundbeck A/S
      1. Overview
      2. Key Strategies
      3. Recent Developments
    3. INSYS Therapeutics, INC.
      1. Overview
      2. Key Strategies
      3. Recent Developments
    4. CatalystPharma
      1. Overview
      2. Key Strategies
      3. Recent Developments
    5. GW Pharmaceuticals, plc.
      1. Overview
      2. Key Strategies
      3. Recent Developments
    6. Retrophin, Inc.
      1. Overview
      2. Key Strategies
      3. Recent Developments
    7. Mallinckrodt
      1. Overview
      2. Key Strategies
      3. Recent Developments
    8. ORPHELIA Pharma SA
      1. Overview
      2. Key Strategies
      3. Recent Developments
    9. Valerion Therapeutics
      1. Overview
      2. Key Strategies
      3. Recent Developments
  10. SCALAR 360 DEGREE MARKET PERSPECTIVE
  11. APPENDIX 
Please submit your enquiry below so our representative can get in touch with you
*
*
*
*
*
*

USA - CANADA TOLL FREE
+1-800-213-5170

EMAIL
sales@scalarmarketresearch.com

Benefits of Buying From Scalar

Unparalleled Expertise

Our industry experts hold inimitable know-how across wide range of industry verticals

Assured Quality

We deliver high-quality, real-time and data-driven industry insights to our clients

24x7 Analyst Support

We offer pre-purchase and post-purchase support from our industry experts

Privacy & Security

All your personal information and confidential details are safe and secure with us